Last checked at 23 Oct 2018 15:59
UK Shareholder Meetings Calendar - Next 7 Days
Wednesday 24 OctoberIndigovisionBeeks FinancialReddePhoto-Me 25 & Smart 26 29 30
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Scancell Holdings Share News (SCLP)
SCLP Share
Price
SCLP Share
News
SCLP Share
Chat
SCLP Share
Trades16
SCLP
Live RNS
SCLP Share
Charts
SCLP Level 2
Console
SCLP Live
Share Price
SCLP Broker
Ratings
SCLP Directors
Deals
SCLP Financial
Diary
SCLP
Fundamentals
SCLP Short
Positions
SCLP
Media
Scancell Holdings Information
Share Price Information for Scancell Holdings (SCLP)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
9.875
Bid:
9.50
Ask:
10.25
Change:
0.00 (0.00%)
Spread:
0.75 (7.895%)
Open:
9.875
High:
9.875
Low:
9.72
Prev. Close:
9.875
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Scancell Holdings updates on clinical trial of melanoma vaccine
Tue, 29th Jan 2013 09:05
Scancell Holdings said Tuesday it edged closer to completing clinical trials of a vaccine for the treatment of melanoma. The developer of therapeutic cancer vaccines recruited and treated the final patient in the second phase of tests for SCIB1, a DNA ImmunoBody injection.The trial is being conducted in five UK centres in patients with Stage III/IV disease to assess the safety of the treatment and the immune response. Patients are being treated with a 4.0mg dose of SCIB1, five times over six months. Last month Scandell released findings from the first phase of the study which showed SCIB1 produced an immune response that may benefit patients with malignant melanoma. At the same the group also announced approval from regulators to treat an extra group of patients with a higher 8.0mg dose of the vaccine."As expected, the recruitment of patients in the second part of the trial proceeded faster than recruitment for the first part of the trial, as we were not constrained by the cohort study design requiring sequential dose escalation, and there were more patients available with earlier stage disease," said Lindy Durrant, Joint Chief Executive Officer (CEO) of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University."The recruitment and dosing of the final patient in part two gives us confidence that this phase of the study will be completed by the end of 2013, consistent with previous expectations."Shares were down 0.59% to 42.25p at 9:19 Tuesday. RD
More News
25 Sep 2018 11:51
Scancell Well Placed To Keep Pushing Forward Cancer Treatment Work
LONDON (Alliance News) - Immunotherapy firm Scancell Holdings PLC on Tuesday said it is well funded to progress its range of proposed cancer immunotherapies.Scancell is developing for based
Read more18 Sep 2018 16:19
UK Earnings, Trading Statements Calendar - Next 7 Days
Wednesday 19 September KingfisherHalf Year ResultsBabcock InternationalTrading Year Year
Read more24 Jul 2018 12:26
Hygea VCT Net Asset Value Shrinks In First Half On Portfolio Value
LONDON (Alliance News) - Hygea VCT PLC on Tuesday said net asset value decreased in the first half of its current financial year due to a fall in value of its AIM-listed portfolio in the venture a
Read more23 May 2018 14:29
Scancell To Receive European Patent For Moditope Platform In June
LONDON (Alliance News) - Scancell Holdings PLC on Wednesday said it will secure a European patent for its Moditope immunotherapy platform in mid-June.The cancer treatment developer said the
Read more8 May 2018 11:16
Scancell Holdings Raises GBP1.2 Million Via Share Open Offer (ALLISS)
LONDON (Alliance News) - Scancell Holdings PLC said Tuesday that it has raised GBP1.2 million through an open offer of 10.1 million shares at a price of 12.0 pence per share.Shares in the a
Read more3 May 2018 13:43
Hygea VCT Increases NAV Per Share, Changes RBS Overdraft To Loan
LONDON (Alliance News) - Hygea VCT PLC said on Thursday its net present value per share increased in the recent quarter.At March 31, Hygea's NAV per share was 64.4p, up from 63.8p at of
Read more18 Apr 2018 15:09
UPDATE: Scancell Raises GBP7.5 Million, Makes Antibody Acquisition (ALLISS)
LONDON (Alliance News) - Immunotherapy developer Scancell Holdings PLC said Wednesday that it raised GBP7.5 million via a placing of 57.4 million shares and a subscription of 5.0 million shares at
Read more18 Apr 2018 11:44
Scancell Announces GBP8 Million Fundraise, Makes Antibody Acquisition (ALLISS)
LONDON (Alliance News) - Immunotherapy developer Scancell Holdings PLC said Wednesday that it will raise up to GBP8.0 million via equity issue and also announced a technology shares were down 20%
Read more3 Apr 2018 11:02
Scancell Signs Manufacturing Agreement With PolyPeptide Group
LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC said on Tuesday it has signed a manufacturing agreement with therapeutic peptide manufacturer the f T
Read more19 Oct 2016 11:05
10 Oct 2016 11:42
Scancell to develop ImmunoBody lung cancer treatment
(ShareCast News) - Cancer immunotherapy development company Scancell Holdings announced on Monday its intention to develop its SCIB2 ImmunoBody for the treatment of non-small cell lung cancer in combination with a checkpoint inhibitor. The AIM-traded firm's board approved the decision based on the o
Read more16 Sep 2016 14:24
Scancell Holdings widens full year loss on US investment
(ShareCast News) - Scancell Holdings, a developer of novel immunotherapies for the treatment of cancer, has reported a third consecutive full year loss due to the costs involved in its expansion in the US. The firm has seen a 3% increase in its operating loss over the last three years. The loss was
Read more